Fioravanti et al. reported that visfatin levels were substantially reduced in non-diabetic individuals after three weeks of weight-loss therapy, but the reverse was observed with regard to the serum visfatin levels in T2DM patients [66]. This evidence concerns the gene NAMPT and type 2 diabetes mellitus.